HolderBook

RTW INVESTMENTS, LP

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1493215
Reported value
$11.7B
Positions
84
Top 10 weight
47.7%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
MADRIGAL PHARMACEUTICALS INCMDGL$1.1B1,993,6879.14%-1.25pp13qHELD
ARGENX SEARGX$658.2M709,4465.62%+0.46pp31qHELD
PTC THERAPEUTICS INCPTCT$631.9M7,746,4155.39%+0.14pp31qHELD
PROTAGONIST THERAPEUTICS INCPTGX$620.4M5,061,1755.30%-0.01pp28qHELD
CG ONCOLOGY INCCGON$605.0M8,514,5905.16%+0.46pp10q+21.9%+$108.7M
INSMED INCINSM$516.3M4,842,8804.41%-3.47pp13qHELD
TANGO THERAPEUTICS INCTNGX$434.5M13,900,6203.71%+0.94pp3q+4.5%+$18.8M
SPYRE THERAPEUTICS INCSYRE$377.5M4,251,9963.22%+1.13pp11q+1.9%+$7.1M
CELCUITY INCCELC$345.8M3,304,9032.95%-0.50pp3q+8.7%+$27.8M
ERASCA INCERAS$328.8M17,946,7542.81%+0.21pp3q+11.1%+$32.8M
RADNET INCRDNT$298.9M4,846,9582.55%+0.17pp11q+13.1%+$34.7M
ORUKA THERAPEUTICS INCORKA$298.7M3,139,0302.55%+1.55pp8q+52.5%+$102.9M
NATERA INCNTRA$271.4M1,000,0002.32%-0.17pp28q-20.0%-$67.9M
ULTRAGENYX PHARMACEUTICAL INRARE$260.3M7,796,8952.22%+1.46pp19q+113.7%+$138.5M
IRHYTHM HOLDINGS INCIRTC$259.6M2,182,6312.22%+0.26pp3q+30.8%+$61.2M
CYTOKINETICS INCCYTK$243.8M2,862,0032.08%+0.30pp24q+5.2%+$12.0M
KAILERA THERAPEUTICS INCKLRA$237.4M10,776,8202.03%-newNEW
ESTABLISHMENT LABS HLDGS INCESTA$227.9M2,655,6951.95%+0.45pp31qHELD
GUARDANT HEALTH INCGH$222.2M1,481,0331.90%+0.54pp5qHELD
NEUROCRINE BIOSCIENCES INCNBIX$213.7M1,267,9251.82%+0.43pp5q+19.4%+$34.7M
TARSUS PHARMACEUTICALS INCTARS$211.3M3,357,0591.80%-0.53pp23qHELD
STOKE THERAPEUTICS INCSTOK$184.0M5,623,5251.57%-0.25pp29qHELD
UNIQURE NVQURE$181.5M3,941,5721.55%+1.13pp8q+52.4%+$62.4M
ACADIA PHARMACEUTICALS INCACAD$180.8M7,144,5241.54%-0.04pp17qHELD
REPLIGEN CORPRGEN$169.3M1,240,6371.45%+0.03pp3q+2.9%+$4.7M
UROGEN PHARMA LTDURGN$167.2M4,543,8951.43%+0.61pp20qHELD
GH RESEARCH PLCGHRS$159.5M5,933,8151.36%+0.53pp21qHELD
IMMUNOCORE HLDGS PLCIMCR$154.6M4,869,7981.32%-0.14pp22qHELD
COMPASS PATHWAYS PLCCMPS$151.4M10,700,9741.29%+0.71pp7q+0.6%+$970.5K
IMMATICS N.VIMTX$131.1M12,946,1761.12%-0.14pp24q+0.6%+$778.3K
ZAI LAB LTDZLAB$124.9M6,574,0321.07%-0.16pp7qHELD
IMMUNOVANT INCIMVT$122.4M3,177,8491.05%+0.26pp3qHELD
BELITE BIO INCBLTE$110.2M715,3320.94%-0.19pp4qHELD
XENCOR INCXNCR$109.1M6,777,4610.93%+0.12pp8qHELD
TAYSHA GENE THERAPIES INCTSHA$92.3M13,560,2580.79%+0.18pp12q-0.9%-$817.1K
COGENT BIOSCIENCES INCCOGT$89.4M2,309,0210.76%-1.33pp4q-57.7%-$121.9M
ALKERMES PLCALKS$87.6M1,672,3560.75%+0.16pp12qHELD
STRUCTURE THERAPEUTICS INCGPCR$86.3M1,607,5070.74%-newNEW
REPLIMUNE GROUP INCREPL$82.0M7,411,5810.70%+0.14pp9q+0.7%+$605.1K
CASTLE BIOSCIENCES INCCSTL$66.3M2,778,3350.57%-0.11pp3q+0.7%+$477.0K
CANDEL THERAPEUTICS INCCADL$66.1M6,422,0180.56%+0.25pp2qHELD
ROCKET PHARMACEUTICALS INCRCKT$60.5M17,687,7720.52%-0.11pp31qHELD
KODIAK SCIENCES INCKOD$58.0M1,487,9340.49%-0.07pp3qHELD
AKTIS ONCOLOGY INCAKTS$51.3M1,592,0430.44%+0.15pp2qHELD
AXOGEN INCAXGN$46.7M1,011,5760.40%-newNEW
DANAHER CORP DELDHR$43.8M230,0000.37%-newNEW
CULLINAN THERAPEUTICS INCCGEM$43.1M2,364,3470.37%+0.13pp9q+38.6%+$12.0M
NEUROGENE INCNGNE$42.8M1,362,4560.37%+0.09pp10qHELD
HINGE HEALTH INCHNGE$41.5M500,0000.35%-0.39pp3q-74.1%-$118.7M
ORCHESTRA BIOMED HLDGS INCOBIO$41.2M9,556,0630.35%flat14q+15.0%+$5.4M
SOLID BIOSCIENCES INCSLDB$38.9M3,892,9260.33%-newNEW
SAVARA INCSVRA$36.7M5,952,3800.31%-0.01pp3qHELD
AQUESTIVE THERAPEUTICS INCAQST$30.9M7,426,4710.26%-0.04pp4qHELD
KYMERA THERAPEUTICS INCKYMR$27.5M240,0000.23%+0.04pp3qHELD
VERASTEM INCVSTM$25.3M6,635,7930.22%-0.13pp6q+0.9%+$227.2K
DIANTHUS THERAPEUTICS INCDNTH$24.2M248,0630.21%flat2qHELD
BETA BIONICS INCBBNX$23.5M1,500,0000.20%flat6q-25.0%-$7.8M
CENTURY THERAPEUTICS INCIPSC$21.3M8,695,6520.18%-0.01pp2qHELD
EVOMMUNE INCEVMN$20.0M1,502,2350.17%-0.17pp3qHELD
BEAM THERAPEUTICS INCBEAM$19.6M570,3940.17%+0.03pp3qHELD
DEFINIUM THERAPEUTICS INCDFTX$18.8M400,0000.16%+0.10pp2q+33.3%+$4.7M
IDEAYA BIOSCIENCES INCIDYA$13.8M370,3700.12%-newNEW
ATAIBECKLEY INCATAI$10.5M2,000,0000.09%+0.02pp2qHELD
MILESTONE PHARMACEUTICALS INMIST$10.5M7,833,3360.09%+0.01pp29q+23.7%+$2.0M
OCUGEN INCOCGN$10.2M6,666,6660.09%-0.03pp2qHELD
TENAX THERAPEUTICS INCTENX$10.1M696,5700.09%+0.03pp6q+88.1%+$4.7M
HEARTFLOW INCHTFL$8.7M295,0000.07%-0.05pp4q-40.4%-$5.9M
PERCEPTIVE CAP SOLUTIONS CORPCSC$8.1M742,5000.07%-0.01pp9qHELD
WAVE LIFE SCIENCES LTDWVE$7.8M1,350,0000.07%-0.03pp8qHELD
LARIMAR THERAPEUTICS INCLRMR$7.8M2,565,9990.07%flat4q+71.1%+$3.3M
LUMEXA IMAGING HOLDINGS INCLMRI$7.3M650,0000.06%+0.01pp3qHELD
ALLOGENE THERAPEUTICS INCALLO$6.8M3,250,0000.06%-newNEW
CRESCENT BIOPHARMA INC.CBIO$6.7M372,8560.06%-0.01pp3qHELD
4D MOLECULAR THERAPEUTICS INFDMT$6.3M475,7370.05%+0.01pp3qHELD
MAZE THERAPEUTICS INCMAZE$6.3M212,0000.05%-newNEW
CAPRICOR THERAPEUTICS INCCAPR$6.0M250,0000.05%-0.02pp3qHELD
KALARIS THERAPEUTICS INCKLRS$5.3M1,300,0000.05%-0.03pp3qHELD
ABIVAX SAABVX$3.5M26,4000.03%-newNEW
AVALO THERAPEUTICS INCAVTX$3.2M175,0000.03%-0.10pp2q-79.6%-$12.6M
MEDLINE INCMDLN$2.8M70,0000.02%-0.01pp3qHELD
DISC MEDICINE INCIRON$2.2M30,0000.02%flat3qHELD
IMAGENEBIO INCIMA$2.0M334,4450.02%flat4qHELD
EXAGEN INCXGN$906.8K195,0000.01%flat28q-50.7%-$931.1K
ROCKET PHARMACEUTICALS INCRCKTW$1.2K350,0000.00%flat14qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 81.6%Healthcare Services 10.4%Medical Devices 5.2%Other sectors 0.7%Not classified 2.1%
 
SectorValueShare
Biotech & Pharma$9.6B81.6%
Healthcare Services$1.2B10.4%
Medical Devices$610.4M5.2%
Other sectors$85.3M0.7%
Not classified$245.5M2.1%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+17.8%+14.8%+2.9%98%
Q1 2026-4.6%-4.6%+0.0%99%
Q4 2025+23.2%+2.4%+20.8%97%
Q3 2025+25.2%+7.8%+17.3%100%
Q2 2025+4.1%+10.5%-6.3%100%
Q1 2025-2.7%-4.6%+1.8%100%
Q4 2024-3.2%+2.1%-5.3%100%
Q3 2024+4.6%+5.4%-0.8%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$11.7B8492481347.7%45
Q1 2026$10.0B88925121250.0%45
Q4 2025$10.0B912920121250.5%48
Q3 2025$8.1B74101412952.6%45
Q2 2025$7.0B7311216650.0%45
Q1 2025$6.5B68111561552.7%45
Q4 2024$6.6B7291916548.6%45
Q3 2024$6.9B681114101146.1%45
Q2 2024$6.5B6872211848.8%45
Q1 2024$6.8B69162361145.1%45
Q4 2023$6.4B641412201753.2%45
Q3 2023$4.7B6710166555.8%45
Q2 2023$5.3B6210191853.6%45
Q1 2023$4.8B60818152555.5%45
Q4 2022$4.9B7711991055.2%45
Q3 2022$4.3B86415212548.9%45
Q2 2022$3.9B107102712945.3%46
Q1 2022$4.8B106220282038.7%46
Q4 2021$6.8B1241722151338.3%45
Q3 2021$6.6B120202381341.1%46
Q2 2021$6.6B113151781345.0%44
Q1 2021$6.4B111183016942.9%44
Q4 2020$6.0B1022621101447.6%47
Q3 2020$4.2B9022355945.3%47
Q2 2020$3.6B7717317548.4%45
Q1 2020$2.3B657372350.6%45
Q4 2019$2.7B61133091254.6%45
Q3 2019$1.7B6015149755.0%45
Q2 2019$1.9B5282810660.4%45
Q1 2019$1.5B5082410558.2%45
Q4 2018$1.1B47000062.6%46

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.